Activity of cabozantinib after immunotherapy in advance kidney cancer
A retrospective study published in the European Journal of Cancer [...]
Potential biomarker for response to nivolumab for kidney cancer
Nivolumab was the first immunotherapy to be approved for the [...]
Ipilimumub plus nivolumab combination after prior treatment with immune checkpoint inhibitors
This retrospective study published in the Journal of Clinical Oncology [...]
ASCO 2020: Implications of the research presented at ASCO 2020 on the treatment of advanced kidney cancer
In this video presentation, Dr Toni Chouieri discusses the SAVOIR, [...]
Combination immunotherapy plus VEGFR inhibitor for favourable risk and elderly kidney cancer patients
A study published in Clinical Genitourinary Cancer this month looks [...]
ASCO 2020: Lenvatinib plus pembrolizumab for disease progression after immunotherapy for metastatic kidney cancer
Results from a phase II trial of a combination of [...]
Safety and efficacy of immunotherapy rechallenge in patients with kidney cancer
There are a number of immune checkpoint inhibitor drugs available [...]
ASCO 2020: Nivolumab plus ipilimumab combination for previously treated kidney cancer
Results from the phase II FRACTION-RCC clinical trial to assess [...]
ASCO 2020: Factors influencing outcomes in kidney cancer treated with immunotherapy
A study presented during the 2020 American Society of Clinical [...]
Combination of vaccinia virus plus immune checkpoint inhibitor for advanced kidney cancer
Results from a phase Ib study of a vaccinia virus [...]
